Nov 13 2009, 5:12 PM EST
News source: Business Wire
Talecris Biotherapeutics (Nasdaq: TLCR) and N.C. Gov. Bev Perdue jointly announced today that the company will expand its manufacturing facilities in Clayton, creating 259 new jobs over the next seven years. The company plans to spend $268.7 million to expand their facilities in Clayton. State and local tax credits and incentive grants will be provided to facilitate the expansion.
“We’re extremely pleased to be investing in our company’s growth while at the same time contributing to the economic prosperity of Johnston County, a region that has been a historic partner in the development of our industry,” said Mary Kuhn, executive vice president of Operations at Talecris. “Our manufacturing capabilities have grown exponentially in recent years, creating more jobs and local opportunities. We’re excited to continue expanding our business in a region that has been so supportive of the biotechnology industry.”
Talecris currently employs approximately 4,700 people worldwide and is headquartered in the biotechnology hub of Research Triangle Park, N.C. With more than 1,800 full-time workers employed in Johnston County, Talecris is one of the county’s largest employers. The company has hired more than 180 employees this year in Johnston County alone.
The Clayton manufacturing facility produces protein therapies that are used to treat a range of diseases, including immune deficiencies, hemophilia, genetic emphysema, and a rare neurological disorder known as chronic inflammatory demyelinating polyneuropathy (CIDP). Talecris has eleven approved products on the market, each of them derived from human plasma that is collected primarily from the company’s 71 plasma donation centers nationwide.
To facilitate Talecris’ manufacturing expansion, the state has awarded the company a $250,000 grant from the state’s One North Carolina Fund. In addition, the state Economic Investment Committee today voted to award a Job Development Investment Grant to Talecris.
“The competition for these types of jobs is fierce,” Perdue said. “The fact that Talecris has found the tools it needs to succeed in North Carolina demonstrates why this state’s business climate is consistently named as the best in the nation.”
For more information about Talecris Biotherapeutics, including job opportunities, visit www.talecris.com.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com.
Cautionary statement regarding forward-looking statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, quotations from management in this press release, statements regarding strategic and operation plans, and statements regarding the development or commercialization of therapies. Forward-looking statements are based on current beliefs and expectations and are subject to inherent risks and uncertainties. You are cautioned not to place undue reliance on forward-looking statements. Although Talecris believes that the forward-looking statements contained in this press release are reasonable, there is no assurance that expectations will be fulfilled.
The following factors, among others, could cause actual results to differ materially from those expressed or implied in forward-looking statements: possible U.S. legislation or regulatory action affecting, among other things, the U.S. healthcare system, pharmaceutical pricing and reimbursement, including Medicaid and Medicare; our ability to procure adequate quantities of plasma and other materials which are acceptable for use in our manufacturing processes from our own plasma collection centers or from third-party vendors; our ability to maintain compliance with government regulations and licenses, including those related to plasma collection, production and marketing; our ability to identify growth opportunities for existing products and our ability to identify and develop new product candidates through our research and development activities; and the timing of, and our ability to, obtain and/or maintain regulatory approvals for new product candidates, the rate and degree of market acceptance, and the clinical utility of our products. Additional information about factors that could affect the business and financial results of Talecris is contained in its final Prospectus filed pursuant to Rule 424(b)(1) with the Securities and Exchange Commission on October 1, 2009. Talecris undertakes no duty to update any forward-looking statement.
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All